Intervention

Thymalfasin

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common conditions6

Lead sponsors shown2

Clinical trials

3 shown

Abscopal Effect for Metastatic Non-small Cell Lung Cancer.NCT02542930 · 2016-01-01

WITHDRAWN

Abscopal Effect for Metastatic Small Cell Lung CancerNCT02542137 · 2015-09-01

WITHDRAWN

The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of InfectionNCT00001036

COMPLETED

Common conditions

Radiotherapy2 Thymalfasin2 HIV Infections1 Metastatic Non-small Cell Lung Cancer1 Non-small Cell Lung Cancer1 Small Cell Lung Cancer1

Leading sponsors

Zhejiang Provincial People's Hospital 2 National Institute of Allergy and Infectious Diseases (NIAID) 1

Trial status mix

WITHDRAWN2

COMPLETED1

Phase mix

PHASE22

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.